GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Beginning Cash Position

Biogen (BUE:BIIB) Beginning Cash Position : ARS884,541 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Biogen Beginning Cash Position?

Biogen's Beginning Cash Position for the quarter that ended in Mar. 2024 was ARS884,541 Mil.

Biogen's quarterly Beginning Cash Position declined from Sep. 2023 (ARS916,099 Mil) to Dec. 2023 (ARS825,932 Mil) but then increased from Dec. 2023 (ARS825,932 Mil) to Mar. 2024 (ARS884,541 Mil).

Biogen's annual Beginning Cash Position increased from Dec. 2021 (ARS134,438 Mil) to Dec. 2022 (ARS379,124 Mil) and increased from Dec. 2022 (ARS379,124 Mil) to Dec. 2023 (ARS1,234,367 Mil).


Biogen Beginning Cash Position Historical Data

The historical data trend for Biogen's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Beginning Cash Position Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73,198.75 237,116.90 134,437.89 379,123.70 1,234,367.30

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 675,482.73 695,568.00 916,099.14 825,931.90 884,540.76

Biogen Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Biogen Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Biogen's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BUE:BIIB) Headlines